Key result
W7 restored the balance of strongly bound myosin heads to F-actin at high Ca2+ and relaxation in E173A mutant muscle fibers, suggesting potential to reduce mutation-induced contractility damage.
Why the study?
Substitution of Ala for Glu in position 173 of γ-tropomyosin (Tpm3.12) is associated with muscle weakness, but the underlying critical conformational changes in myosin, actin, and tropomyosin remained to be determined.
The troponin Ca2+ sensitivity inhibitor W7 can mitigate the damaging molecular effects of the E173A mutation in γ-tropomyosin, suggesting a potential therapeutic approach for associated muscle weakness.
Preclinical correction of myosin-actin defects by W7 in mutant models; leaves open translation to human therapy for tropomyosin myopathies.
Substitution of Ala for Glu residue in position 173 of γ-tropomyosin (Tpm3.12) is associated with muscle weakness. Here we observe that this mutation increases myofilament Ca2+-sensitivity and inhibits in vitro actin-activated ATPase activity of myosin subfragment-1 at high Ca2+. In order to determine the critical conformational changes in myosin, actin and tropomyosin caused by the mutation, we used the technique of polarized fluorimetry. It was found that this mutation changes the spatial arrangement of actin monomers and myosin heads, and the position of the mutant tropomyosin on the thin filaments in muscle fibres at various mimicked stages of the ATPase cycle. At low Ca2+ the E173A mutant tropomyosin shifts towards the inner domains of actin at all stages of the cycle, and this is accompanied by an increase in the number of switched-on actin monomers and myosin heads strongly bound to F-actin even at relaxation. Contrarily, at high Ca2+ the amount of the strongly bound myosin heads slightly decreases. These changes in the balance of the strongly bound myosin heads in the ATPase cycle may underlie the occurrence of muscle weakness. W7, an inhibitor of troponin Ca2+-sensitivity, restores the increase in the number of myosin heads strongly bound to F-actin at high Ca2+ and stops their strong binding at relaxation, suggesting the possibility of using Ca2+-desensitizers to reduce the damaging effect of the E173A mutation on muscle fibre contractility.
No takes yet. Share an insight, caveat, or question.
Borovikov et al. (2020) studied Muscle weakness associated with E173A mutation in Tpm3.12. W7 (troponin Ca2+ sensitivity inhibitor) was evaluated on Spatial arrangement of actin monomers and myosin heads, and position of mutant tropomyosin. W7 restored the balance of strongly bound myosin heads to F-actin at high Ca2+ and relaxation in E173A mutant muscle fibers, suggesting potential to reduce mutation-induced contractility damage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: